MarketCap
Facebook
X
Telegram
Aptevo Therapeutics Long-Term Debt | APVO
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Aptevo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.76 M | 4.63 M | 5.4 M | 1.46 M | 3.71 M | 5 M | - | 19.3 M | 15.7 M | 18.4 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.3 M | 1.46 M | 8.59 M |
Quarterly Long-Term Debt Aptevo Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.53 M | 3.99 M | 4.21 M | 4.42 M | 4.63 M | 4.8 M | 5 M | 5.2 M | 5.4 M | 5.6 M | 5.7 M | 5.9 M | 1.46 M | 6.2 M | 6.4 M | 1.1 M | 3.71 M | 1.61 M | 1.87 M | 2.12 M | 28.2 M | 2.36 M | 2.36 M | 2.36 M | 3.33 M | 3.33 M | 19.6 M | 19.4 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.2 M | 1.1 M | 9.43 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
1.56 M | $ 5.71 | 7.24 % | $ 700 M |  USA |
 |
Фармсинтез
LIFE
|
13.2 M | - | - | - |  Russia |
 |
AbbVie
ABBV
|
64.5 B | $ 261.51 | 1.66 % | $ 463 B | USA |
 |
AbCellera Biologics
ABCL
|
137 M | $ 11.09 | 1.84 % | $ 3.31 B |  Canada |
 |
Agenus
AGEN
|
30.5 M | $ 7.16 | 3.17 % | $ 213 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
4.05 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
43.6 M | - | -14.46 % | $ 27.9 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
281 K | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
50.2 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
7.81 M | $ 5.39 | 0.28 % | $ 285 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
21.8 M | $ 33.38 | 0.16 % | $ 1.94 B | USA |
 |
Adagene
ADAG
|
1.14 M | $ 3.29 | 2.94 % | $ 194 M |  China |
 |
iTeos Therapeutics
ITOS
|
3.76 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
44 K | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
127 M | $ 24.82 | 2.56 % | $ 3.77 B | USA |
 |
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
10.8 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
84.7 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
38.2 M | - | - | $ 28.6 M | USA |
 |
MediWound Ltd.
MDWD
|
2.01 M | $ 13.84 | 5.57 % | $ 377 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
9 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
806 K | $ 5.12 | 0.1 % | $ 981 M | Canada |
 |
ADC Therapeutics SA
ADCT
|
1.03 M | $ 1.11 | 3.76 % | $ 141 M |  Schweiz |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
1.29 M | - | 17.91 % | $ 11.1 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
151 K | $ 4.97 | 1.43 % | $ 3.32 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
40.6 M | $ 27.48 | 0.04 % | $ 4.63 B | USA |
 |
AIM ImmunoTech
AIM
|
927 K | $ 0.22 | 0.05 % | $ 356 K | USA |
 |
ADMA Biologics
ADMA
|
69.3 M | $ 9.15 | 0.16 % | $ 2.18 B | USA |
 |
Axcella Health
AXLA
|
25.1 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
20.9 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
60.3 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
22.7 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
11.2 M | $ 7.28 | 3.12 % | $ 317 M | USA |
 |
Baudax Bio
BXRX
|
1.52 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
136 K | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
467 K | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
34.9 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
4.72 M | - | - | $ 3.74 B | USA |
 |
Akebia Therapeutics
AKBA
|
48.2 M | $ 0.98 | 3.01 % | $ 252 M | USA |
 |
Avid Bioservices
CDMO
|
54.2 M | - | - | $ 789 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
380 M | - | - | $ 7.29 B | USA |
 |
AC Immune SA
ACIU
|
3.69 M | $ 2.67 | 2.6 % | $ 269 M | Schweiz |
 |
Alector
ALEC
|
9.32 M | $ 2.22 | 3.74 % | $ 229 M | USA |